Erythropoiesis-Stimulating Agents (ESAs)

High-yield Verified · Oct 2026

Prototype: epoetin alfa

Erythropoiesis-Stimulating Agents (ESAs) are a class of medications used for anemia of chronic kidney disease.

Synthetic erythropoietin — it tells the marrow to make more red cells, but a higher hemoglobin is not safer.

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 Erythropoietin — the kidney’s red-cell signal

Red-cell production is controlled by a hormone called erythropoietin (EPO), made by the kidney in response to low oxygen. EPO travels to the bone marrow and tells it to make more red cells. In chronic kidney disease, the damaged kidney can’t make enough EPO, so patients become anemic despite adequate iron — a deficiency of the signal, not the raw material.

ESAs are lab-made EPO (epoetin) or a longer-acting version (darbepoetin). They replace the missing signal, raising the red-cell count and reducing the need for transfusions in CKD and in chemotherapy-induced anemia.

Loading diagram…

ESAs replace the erythropoietin signal the failing kidney can no longer make.

02 Why "more blood" can be dangerous — the boxed warning

It seems intuitive that raising hemoglobin toward normal would be good — but large trials found the opposite: driving hemoglobin too high with ESAs increased deaths, heart attacks, strokes, and blood clots. Thicker, more viscous blood and other effects raise thrombotic risk — including clotting of dialysis vascular access. In cancer patients, ESAs also shortened survival and sped tumor progression in several tumor types.

This is the class’s boxed warning, and it reshapes practice: use the lowest dose needed to avoid transfusion, and do not target a normal hemoglobin — no hemoglobin target has been shown to be safe; in CKD on dialysis, reduce or interrupt the dose as hemoglobin approaches 11 g/dL (above 10 g/dL in CKD not on dialysis); with chemotherapy, withhold it once hemoglobin exceeds the level needed to avoid transfusion. Iron must be adequate for the ESA to work, and blood pressure must be watched (ESAs can worsen hypertension).

Loading diagram…

The counterintuitive boxed warning: over-correcting hemoglobin raises thrombosis and death.

Drug names

Generic Brand

epoetin alfa Epogen, Procrit, Retacrit

darbepoetin alfa Aranesp

Indications

Anemia of chronic kidney disease (on or off dialysis)
Chemotherapy-induced anemia (non-curative chemo; lowest dose to avoid transfusion)
Anemia from zidovudine (HIV); reducing allogeneic transfusion in some surgeries

Mechanism of action

Recombinant human erythropoietin binds erythropoietin receptors on marrow erythroid progenitors, stimulating red-cell production. Darbepoetin is a hyperglycosylated, longer-acting analog (less frequent dosing).

In plain terms

They act like the kidney’s natural signal telling the bone marrow to make more red blood cells.

Therapeutic effects — what you'll see working

Success is a gradual hemoglobin rise that avoids transfusion — not a normal hemoglobin. Titrate slowly, ensure iron is replete, and never chase a normal number.

↑ Red-cell production Fewer transfusions

↑ Red-cell production: Stimulates the marrow to raise hemoglobin over weeks, reducing transfusion need in CKD/chemo anemia; ESAs have not been shown to improve quality of life, fatigue, or well-being.
Fewer transfusions: The goal is avoiding blood transfusion and its risks — achieved at the lowest effective dose, not by normalizing hemoglobin.

Adverse effects

The main concerns are the boxed-warning thrombotic/mortality risk of over-correction, plus hypertension and the requirement for adequate iron.

Common

Hypertension (or worsening of it), headache, injection-site reactions, arthralgia; functional iron deficiency.

Blood pressure often rises — after epoetin alfa was started, about 25% of dialysis patients needed antihypertensive therapy started or increased (about 40% of CKD patients early in darbepoetin studies) — so monitor closely. Rapid erythropoiesis consumes iron, so iron stores must be maintained or the ESA won’t work.

■ Boxed warning Hold & notify

Increased death, MI, stroke, venous thromboembolism, and vascular-access thrombosis; shortened survival / tumor progression in some cancers.

Targeting hemoglobin > 11 g/dL raised serious cardiovascular and thrombotic events, and no hemoglobin target, dose, or dosing strategy has been shown not to increase these risks. In cancer, use ESAs only for anemia from myelosuppressive chemotherapy — they are not indicated when the anticipated outcome is cure — and discontinue them when the chemotherapy course is completed. Around surgery, epoetin alfa’s box recommends DVT prophylaxis because of the increased DVT risk. Use the lowest dose that reduces the need for transfusion.

Contraindications

The contraindications flag uncontrolled hypertension, the cancer settings where ESAs shorten survival, pure red cell aplasia, serious allergic reactions, and benzyl-alcohol multiple-dose vials in neonates, infants, and pregnant or breastfeeding women.

Uncontrolled hypertension

ESAs raise blood pressure, and hypertensive encephalopathy and seizures have been reported in CKD — blood pressure must be controlled before and during treatment.

Curative-intent cancer chemotherapy

ESAs can accelerate tumor progression and shorten survival — avoided when the goal of chemo is cure.

Epoetin alfa around cardiac or vascular surgery (or for patients donating their own blood before surgery) use caution

Not an approved use (label limitations); in trials, ESAs increased the risk of death in patients having coronary artery bypass surgery and the risk of DVT with orthopedic surgery.

Pure red cell aplasia from prior ESA (anti-EPO antibodies)

Neutralizing antibodies to erythropoietin cause severe anemia; the ESA is permanently discontinued and the patient is not switched to another ESA.

Serious allergic reaction to the ESA

Anaphylaxis, angioedema, bronchospasm, rash, and urticaria can occur — the drug is stopped immediately and permanently.

Epoetin alfa multiple-dose vials (Epogen, Procrit, Retacrit — benzyl alcohol) in neonates, infants, pregnant women, or breastfeeding women

Benzyl alcohol has caused serious and fatal reactions, including “gasping syndrome,” in neonates and infants, with a potential risk to a fetus or breastfed infant — use a single-dose vial and do not mix with bacteriostatic saline.

Labs & levels

Test Therapeutic / normal Toxic / critical

Hemoglobin (Hgb) CKD: at least weekly when starting or adjusting the dose until stable, then at least monthly; reduce the dose if Hgb rises more than 1 g/dL in any 2-week period Therapeutic No safe target; CKD on dialysis: reduce/interrupt as Hgb approaches 11 g/dL (CKD not on dialysis: above 10 g/dL); chemotherapy: start only if Hgb is below 10 g/dL with at least 2 more months of chemotherapy planned, and withhold above the level needed to avoid transfusion —

Blood pressure Monitor regularly — ESAs can raise/worsen hypertension Normal range < 120/80 mmHg (normal) —

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Monitoring

Monitor hemoglobin and reduce or interrupt the dose if it approaches/exceeds 11 g/dL in CKD on dialysis (exceeds 10 g/dL in CKD not on dialysis); with chemotherapy, withhold it if hemoglobin exceeds the level needed to avoid transfusion; reduce it if hemoglobin rises too fast. Dose increases are made no more often than once every 4 weeks.

Why: Over-correction drives the boxed-warning thrombotic and mortality risk; no hemoglobin target has been shown to be safe, so use the lowest dose that avoids transfusion.

Check blood pressure regularly — control it before and during treatment, and expect the ESA to be reduced or withheld if BP becomes difficult to control — and ensure iron stores are adequate.

Why: ESAs raise BP (hypertensive encephalopathy and seizures have occurred in CKD) and require iron to be effective; without iron the hemoglobin response fails.

In CKD, watch closely for premonitory neurologic symptoms during the first several months, and teach patients to report a new seizure, warning symptoms, or a change in seizure frequency.

Why: Epoetin alfa increases the risk of seizures in patients with CKD.

Patient teaching

Teach the signs of a clot/stroke (leg swelling/pain, chest pain, sudden weakness or speech trouble) and to report them.

Why: Thromboembolism is a boxed-warning risk; early recognition is life-saving.

Common questions

What are Erythropoiesis-Stimulating Agents (ESAs) used for?

Erythropoiesis-Stimulating Agents (ESAs) are used for anemia of chronic kidney disease, chemotherapy-induced anemia, and anemia from zidovudine.

How do Erythropoiesis-Stimulating Agents (ESAs) work?

They act like the kidney’s natural signal telling the bone marrow to make more red blood cells.

What are the serious side effects of Erythropoiesis-Stimulating Agents (ESAs)?

Watch for increased death, MI, stroke, venous thromboembolism, and vascular-access thrombosis; shortened survival / tumor progression in some cancers.

What labs should be monitored with Erythropoiesis-Stimulating Agents (ESAs)?

Monitor hemoglobin (Hgb) (therapeutic no safe target; CKD on dialysis: reduce/interrupt as Hgb approaches 11 g/dL (CKD not on dialysis: above 10 g/dL); chemotherapy: start only if Hgb is below 10 g/dL with at least 2 more months of chemotherapy planned, and withhold above the level needed to avoid transfusion), and blood pressure.

Conditions treated

Anemias

Patho · Hematologic

Replaces the erythropoietin the failing kidneys no longer make in CKD anemia. Started at Hgb < 10 g/dL with a ceiling < 11.5 — the FDA boxed warning exists because targeting above 11 g/dL increased death, cardiovascular events, and stroke. Iron repletion comes first — KDIGO 2026 (as summarized by ERBP) takes a more proactive approach: off dialysis or on peritoneal dialysis, start iron when ferritin is < 100 ng/mL with TSAT < 40%, or ferritin 100–299 ng/mL with TSAT < 25%; on hemodialysis, when ferritin is ≤ 500 ng/mL and TSAT ≤ 30%, preferring IV iron — because elevated hepcidin blocks oral iron; monitor BP (ESAs cause hypertension) and slow the dose if Hgb climbs > 1 g/dL in 2 weeks.

Chronic Kidney Disease & Dialysis

Patho · Renal / Genitourinary

Replaces the erythropoietin the shrinking renal mass no longer makes — started when Hgb < 10 g/dL, with iron repleted first (ferritin < 100 μg/L or TSAT < 20% means iron before ESA). This is a drug with a ceiling, not a target: pushing Hgb above 11 g/dL raises cardiovascular-event risk (FDA boxed warning), the guideline cap is 11.5 g/dL, and uncontrolled hypertension is a contraindication — monitor BP during therapy, and expect a dose cut of ≥ 25% if Hgb climbs more than 1 g/dL in 2 weeks.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.